PDCD1 and lymphoma: The patient was diagnosed as advanced MF (stage IVA1) and was enrolled in a phase IA clinical trial of a humanized IgG4 anti–PD-1 monoclonal antibody (9) in advanced lymphomas and solid tumors (NCT03809767).